Key Highlights
● Amgen closed at $432.49 on October 16, trading above the analyst target.
● The consensus 12-month price target is $394.98, implying about 8.67% downside.
● Analysts are split 12 Buy, 17 Hold, and 5 Sell on the stock.
● Targets range from $225 to $500 across 34 analysts.
Amgen Inc. (NASDAQ:AMGN) closed at $432.49 on October 16, 2026, according to market data. The consensus mean analyst price target, from 34 analysts, is $394.98, which sits 8.7% below the latest price (-8.67%). It is a member of the S&P 500. The consensus target sits below the market price, an unusual set-up that has led to renewed discussion of valuation.
What Is the Latest Analyst Price Target?
The mean target is $394.98 and the median is $405.00. The highest target is $500 and the lowest is $225, so the range between the most optimistic and most cautious forecasts is wide. If the consensus proves accurate, the implied move from the latest close would be -8.7%. Price targets are forecasts, usually set with a 12-month horizon, not guarantees, and they are frequently revised as conditions change. Figures reflect market data in mid-October 2026, and other data providers may show slightly different numbers because of differing coverage and update times.
What Are Analysts Saying?
The consensus rating is Hold, with a split of 12 Buy, 17 Hold, 5 Sell. Recent actions include the following. Wells Fargo maintained Hold at $430 on October 16, 2026. Guggenheim maintained Hold and cut its target from $388 to $378 on 13 October. BMO Capital maintained Hold, lowering its target from $450 to $415, and Citi maintained Hold at $405 on 12 October, while Bank of America Securities reiterated Sell and raised its target from $317 to $328 that day.
Together, these updates show how individual brokers are adjusting their views, and they should be read as snapshots rather than a settled verdict.
What Could Help the Stock Reach the Price Target?
The consensus target suggests potential if conditions develop favourably. On the supportive side, the high target of $500 shows that some analysts see scope for the shares to move further, and the share price is currently above the consensus, which would mean the market is more optimistic than the average broker. Stronger-than-expected results, positive guidance or an improving macroeconomic backdrop could also lead analysts to maintain or raise their forecasts, though none of these outcomes is certain.
What Could Prevent the Stock Reaching the Target?
There are also reasons for caution. The consensus target is below the current price, implying negative upside of about 8.7%, and most analysts rate the stock Hold or Sell. Recent target cuts at Guggenheim and BMO point to caution. Analyst forecasts can prove wrong, and unexpected company developments, weaker demand, cost pressures or a broader market sell-off could all push the shares away from the consensus level. A target is only an estimate of where analysts think the shares might trade, not a prediction that they will get there.
What Should Investors Watch Next?
Investors may wish to follow the company's next quarterly results and any change in guidance, as well as further target revisions from the brokers named above. Movements in the consensus mean, the balance of Buy, Hold and Sell ratings, and the share price relative to the consensus will all be useful indicators of shifting sentiment.
A Premium to Target
With a latest close of $432.49 and a consensus mean target of $394.98, the consensus target suggests an implied -8.7% move from the October 16, 2026 price. Because analysts disagree, as the range of $225 to $500 shows, the forecast should be treated as one input among many.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...